Trial document



drksid header

  DRKS00022250

Trial Description

start of 1:1-Block title

Title

A Randomized, prospektivE pilot triAL on exercising during treatment in FItting TransplaNt Eligible patientS with Symptomatic multiple myeloma

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

REAL-FITNESS

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

Exercising in patients with mutliple myeloma, who received induction therapy (VCD).

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

Symptomatic MM at Initial diagnosis and planned induction therapy VCD (Bortezomib, Cyclophosphamide, Dexamethasone). Two arms receiving/not receiving exercising.

end of 1:1-Block scientific synopsis
start of 1:1-Block forwarded Data

Do you plan to share individual participant data with other researchers?

No

end of 1:1-Block forwarded Data
start of 1:1-Block forwarded Data Content

Description IPD sharing plan:

[---]*

end of 1:1-Block forwarded Data Content
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00022250
  •   2020/10/05
  •   [---]*
  •   yes
  •   Approved
  •   173/20, Ethik-Kommission der Albert-Ludwigs-Universität Freiburg
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  • [---]*
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   C90.0 -  Multiple myeloma
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   exersicing
  •   no exercising
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Interventional
  •   [---]*
  •   Randomized controlled trial
  •   Blinded
  •   patient/subject
  •   Control group receives no treatment
  •   Supportive care
  •   Parallel
  •   N/A
  •   No
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

Feasibility with ist aim of a multicentric, randomised clinical trial.

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

(1) Evaluation of Revised Myeloma Comorbiditiy Index (R-MCI) due to differences in physical active vs. inactive MM-patients. (2) Event Free Survival (EFS).

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • University Medical Center 
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   Actual
  •   2021/01/01
  •   30
  •   Monocenter trial
  •   National
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   18   Years
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

(1) Symptomatic MM at inital diagnosis. (2) Planned induction therapy with VCD followed by transplantation at UKF.

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

(1) Spinal cord compression or unstable fractures. (2) Severe cardial diseases or arrythmia (NYHAE 3-4). (3) Chronic cardial diseases (NYHAE 3-4). (4) Other severe diseases not allowing physical activity and exercising (e. g. severe neurological disorder).

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • Universitätsklinikum Freiburg
    • Hugstetter Strasse 49
    • 79095  Freiburg
    • Germany
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • Universitätaklinikum Freiburg
    • Ms.  Prof. Dr.  Monika  Engelhardt 
    • Hugstetter Str. 55
    • 79106  Freiburg
    • Germany
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Universitätsklinikum Freiburg
    • Ms.  M. A.  Mandy-Deborah  Möller 
    • Breisacher Str. 115
    • 79106  Freiburg
    • Germany
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Universitätsklinikum Freiburg
    • Hugstetter Strasse 49
    • 79095  Freiburg
    • Germany
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting ongoing
  •   [---]*
  •   [---]*
  •   [---]*
  •   [---]*
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.